Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variable Mutation Expression in Human Cancers: A "Hide-and-Seek" Mechanism Linked to Differential MHC-I Presentation Dynamics.

Molecular cancer therapeutics - 5 Jul 2022

Boichard Amélie, Kurzrock Razelle

Abstract excerpt

Not all genomic mutations are expressed at the transcript/protein level, which may explain variation in cancer development, prognosis, and treatment response/resistance. In this study, our aim was to describe the prevalence of somatic mutation loss of expression ('variant silencing') in a large collection of human samples, and the potential impact of such variant silencing on tumor immunogenicity. Whole-exome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation
Share to Histocompatibility Antigens Class I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Mutation, Missense

Share to Neoplasms

Share to Prognosis

Source

Identifiers

PMID: 35545005
DOI: 10.1158/1535-7163.MCT-21-0831

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variable Mutation Expression in Human Cancers: A "Hide-and-Seek" Mechanism Linked to Differential MHC-I Presentation Dynamics.PMID 35545005Read ↗

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.Semantic proximity Read ↗

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumorsSemantic proximity Read ↗

Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors.Semantic proximity Read ↗

INAEME: Integral Neoantigen Analysis with Entirety of Mutational EventsSemantic proximity Read ↗

Massively parallel interrogation of human functional variants modulating cancer immunosurveillanceSemantic proximity Read ↗

Predominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC.Semantic proximity Read ↗

Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in gliomaSemantic proximity Read ↗

Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in gliomaSemantic proximity Read ↗

Massively parallel interrogation of human functional variants modulating cancer immunosurveillance.Semantic proximity Read ↗

Mutant MHC class II epitopes drive therapeutic immune responses to cancer.Semantic proximity Read ↗

Proteogenomic analysis unveils the HLA Class I presented immunopeptidome in melanoma and EGFR mutant lung adenocarcinomaSemantic proximity Read ↗

Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.